Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S376000, C544S315000, C546S209000, C546S271400, C548S229000
Reexamination Certificate
active
07915271
ABSTRACT:
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.
REFERENCES:
patent: 0 294 995 (1988-12-01), None
patent: 0 605 729 (1994-07-01), None
patent: WO 2006/014413 (2006-02-01), None
Ali Amjad
Chen Yi-Heng
Li Hong
Lu Zhijian
Sinclair Peter J.
Daniel Mark R.
McGinnis James L.
Merck Sharp & Dohme Corp.
Young Shawquia
LandOfFree
1,3-oxazolidin-2-one derivatives useful as CETP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2759458